Guosheng Yuan

southern medical university

H指数:13

被引数:595

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy

代谢组学和脂质组学预测接受酪氨酸激酶抑制剂和免疫检查点抑制剂联合治疗的肝细胞癌患者的生存预后

Drug Metabolism and Disposition

IF4

2025-10-290

PRE

TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects

TCR-based细胞免疫疗法在肝细胞癌中的应用：进展、挑战与展望

cancer immunology immunotherapy

IF0

2025-07-010

Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma

低水平病毒血症损害了不可切除肝细胞癌中免疫检查点抑制剂的疗效

LIVER INTERNATIONAL

IF5.2

2025-03-130

OAAI

Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study

酪氨酸激酶抑制剂、免疫检查点抑制剂联合肝动脉灌注奥沙利铂和雷替曲塞与奥沙利铂、5-氟尿嘧啶和亚叶酸钙治疗中晚期肝细胞癌的回顾性研究

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2023-12-013

OAAI

Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma

ANNALS OF ONCOLOGY

IF65.4

2023-11-010

PRE

Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis

BMC INFECTIOUS DISEASES

IF3

2022-07-147

OAAI

Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-06-095

OAAI

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Lenvatinib联合Camrelizumab与Lenvatinib单药治疗不可切除肝细胞癌的一线治疗: 一项多中心回顾性队列研究

FRONTIERS IN ONCOLOGY

IF3.3

2022-02-2428

OAAI

DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the β-catenin pathway

ANNALS OF MEDICINE

IF4.3

2021-03-179

OAAI

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-01-0853

OAAI

Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study

ANNALS OF ONCOLOGY

IF65.4

2020-11-014

OAAI

Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

CLINICAL THERAPEUTICS

IF3.6

2019-08-0147

PREAI

Serum-derived hepatitis C virus can infect human glioblastoma cell line SF268 and activate the PI3K-Akt pathway

MOLECULAR MEDICINE REPORTS

IF3.5

2019-03-191

OAAI

Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals

FRONTIERS IN MICROBIOLOGY

IF4.5

2018-12-049

OAAI

Adaptive mutation F772S-enhanced p7-NS4A cooperation facilitates the assembly and release of hepatitis C virus and is associated with lipid droplet enlargement

EMERGING MICROBES & INFECTIONS

IF7.5

2018-08-083

OAAI

A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study

克服恩替卡韦耐药性需要不同的抑制剂: 回顾性研究中四种救援疗法的比较

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2017-06-184

OAAI

Guosheng Yuan

个人简介

教育背景

工作经历

荣誉奖项

研究方向